U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07374562) titled 'Stellate Ganglion Block for Long COVID Symptoms: A Randomized Controlled Trial' on Jan. 21.
Brief Summary: This single-center, randomized, controlled, single-blind clinical trial evaluates whether a stellate ganglion block (SGB) using bupivacaine can improve persistent symptoms in adults with long COVID. Participants are assigned in a 1:1 ratio to receive either an ultrasound-guided right-sided SGB or a placebo saline injection delivered to the sternocleidomastoid muscle. After the intervention, participants are followed for 26 weeks with scheduled evaluations that include symptom questionnaires and functional tests.
The study asse...